Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,223 Mln
P/E Ratio
--
P/B Ratio
0.76
Industry P/E
--
Debt to Equity
0.14
ROE
-0 %
ROCE
-0.28 %
Div. Yield
0 %
Book Value
20.07
EPS
-0.09
CFO
$1,898.94 Mln
EBITDA
$1,724.94 Mln
Net Profit
$832.05 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Integra LifeSciences Holdings (IART)
| -26.41 | -25.79 | -34.80 | -43.19 | -34.84 | -18.99 | -2.51 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Integra LifeSciences Holdings (IART)
| -47.64 | -22.33 | -16.30 | 3.19 | 11.39 | 29.22 | -5.74 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.58 | 10,289.47 | 14.38 | 12.69 | |
| 73.36 | 9,544.04 | 92.52 | 2.52 | |
| 162.93 | 8,064.21 | -- | -25.23 | |
| 293.06 | 10,728.90 | 773.26 | 1.2 |
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman... Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Address: 1100 Campus Road, Princeton, NJ, United States, 08540 Read more
Executive Chairman
Dr. Stuart M. Essig Ph.D.
Executive Chairman
Dr. Stuart M. Essig Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Integra LifeSciences Holdings (IART) stood at $ 4,037 Mln as on 31-Dec-24
The share price of Integra LifeSciences Holdings (IART) is $16.69 (NASDAQ) as of 24-Apr-2025 12:37 EDT. Integra LifeSciences Holdings (IART) has given a return of -34.84% in the last 3 years.
Integra LifeSciences Holdings (IART) has a market capitalisation of $ 1,223 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Integra LifeSciences Holdings (IART) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Integra LifeSciences Holdings (IART) and enter the required number of quantities and click on buy to purchase the shares of Integra LifeSciences Holdings (IART).
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Address: 1100 Campus Road, Princeton, NJ, United States, 08540
The CEO & director of Dr. Stuart M. Essig Ph.D.. is Integra LifeSciences Holdings (IART), and CFO & Sr. VP is Dr. Stuart M. Essig Ph.D..
There is no promoter pledging in Integra LifeSciences Holdings (IART).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Integra LifeSciences Holdings (IART) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.44
|
|
Operating margin(%)
|
3.25
|
|
Net Margin(%)
|
-0.43
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Integra LifeSciences Holdings (IART) was $0 Mln.
$0.43
(
